Your browser doesn't support javascript.
loading
Alterations in blood proteins in the prodromal stage of bipolar II disorders.
Lee, Hyunju; Han, Dohyun; Rhee, Sang Jin; Kim, Jayoun; Lee, Yunna; Kim, Eun Young; Park, Dong Yeon; Roh, Sungwon; Baik, Myungjae; Jung, Hee Yeon; Lee, Junhee; Lee, Tae Young; Kim, Minah; Shin, Hyunsuk; Kim, Hyeyoon; Kim, Se Hyun; Kwon, Jun Soo; Ahn, Yong Min; Ha, Kyooseob.
Afiliação
  • Lee H; Department of Neuropsychiatry, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
  • Han D; Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Rhee SJ; Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
  • Kim J; Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Lee Y; Department of Neuropsychiatry, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
  • Kim EY; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
  • Park DY; Department of Neuropsychiatry, Kosin University Gospel Hospital, Busan, Republic of Korea.
  • Roh S; Department of Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Baik M; Department of Psychiatry, National Center for Mental Health, Seoul, Republic of Korea.
  • Jung HY; Department of Neuropsychiatry, Hanyang University Hospital, Seoul, Republic of Korea.
  • Lee J; Department of Psychiatry, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
  • Lee TY; Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim M; Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
  • Shin H; Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
  • Kim H; Department of Neuropsychiatry, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
  • Kim SH; Department of Psychiatry, Uijeongbu Eulji Medical Center, Uijeongbu, Republic of Korea.
  • Kwon JS; Department of Neuropsychiatry, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
  • Ahn YM; Department of Neuropsychiatry, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
  • Ha K; Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Sci Rep ; 12(1): 3174, 2022 02 24.
Article em En | MEDLINE | ID: mdl-35210508
ABSTRACT
Although early intervention may help prevent the progression of bipolar disorder, there are some controversies over early pharmacological intervention. In this study, we recruited 40 subjects in the prodromal stage of BD-II (BP), according to bipolar at-risk state criteria. We compared the expression of their plasma proteins with that of 48 BD-II and 75 healthy control (HC) to identify markers that could be detected in a high-risk state. The multiple reaction monitoring method was used to measure target peptide levels with high accuracy. A total of 26 significant peptides were identified through analysis of variance with multiple comparisons, of which 19 were differentially expressed in the BP group when compared to the BD-II and HC groups. Two proteins were overexpressed in the BP group; and were related to pro-inflammation and impaired neurotransmission. The other under-expressed peptides in the BP group were related to blood coagulation, immune reactions, lipid metabolism, and the synaptic plasticity. In this study, significant markers observed in the BP group have been reported in patients with psychiatric disorders. Overall, the results suggest that the pathophysiological changes included in BD-II had already occurred with BP, thus justifying early pharmacological treatment to prevent disease progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Transtorno Bipolar / Proteínas Sanguíneas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Transtorno Bipolar / Proteínas Sanguíneas Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article